KemPharm Inc (KMPH)

0.183 -0.00  -2.43% OTC Markets May 28, 20:00 Delayed 15m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/08/2019 16:30 EST Misc KemPharm Inc Third Quarter Earnings Conference Call in 2019
11/08/2019 Earnings KemPharm Inc Third Quarter Earnings in 2019 Release
08/13/2019 Earnings KemPharm Inc Second Quarter Earnings Results in 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.kempharm.com
  • Investor Relations URL: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-irhome
  • HQ State/Province: Florida
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: N/A
  • Last Earnings Release: Nov. 08, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, ER d-threo-methylphenidate product candidate for the treatment of ADHD, and KP201/IR, APAP-free, single-entity, benzhydrocodone hydrochloride IR abuse-deterrent product candidate designed for the treatment of acute pain.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.